Drug Clinical Trials:
News on drug clinical trials, articles on tests or new drugs and medication.
-
Jun 4th, 2008
Amicus Therapeutics has initiated a Phase 2 clinical trial of AT2220, for the treatment of Pompe disease.
-
Jun 3rd, 2008
Wyeth Pharmaceuticals initiates INTORACT study, a worldwide randomized, open-label, phase 3b study comparing TORISEL plus Avastin versus Avastin plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma.
-
Jun 2nd, 2008
CellCept-based regimen in combination with sirolimus (SRL) is associated with improved renal function when compared with the CellCept-based regimen in combination with calcineurin inhibitors (CNI).
-
Jun 2nd, 2008
Quest PharmaTech's 12-patient, Phase I clinical study entitled "ACP-SL017 Topical Gel: A Phase I Study for the Photodynamic Therapy of Actinic Keratosis" has met both its primary and exploratory objectives.
-
May 30th, 2008
ViroPharma Incorporated completed enrollment in its pivotal Phase 3 study of maribavir in stem cell transplant patients.
-
May 27th, 2008
Favrille announced results from Phase 3 registration trial of Specifid following Rituxan in patients with follicular B-cell non-Hodgkin's lymphoma (NHL).
-
May 27th, 2008
The 56 medical scientists that receive the $600 million funding for medical research will bring new and innovative ways of thinking about biology to the HHMI community.
-
May 23rd, 2008
Tioga Pharmaceuticals announced the results of a recent Phase 2b study of its oral kappa opioid receptor agonist, asimadoline, which demonstrated statistically significant results in the treatment of Irritable Bowel Syndrome.
-
May 23rd, 2008
Amikacin Inhale, currently being studied for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients, achieved over 1000 times greater lung exposure to the antibiotic amikacin as compared to intravenous route of administration.
-
May 23rd, 2008
The use of Advair Diskus 250/50 demonstrated a 30% reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations as compared with salmeterol alone.
